|
Notable gastric cancer research over the past few months includes promising clinical trial results for two novel antibody treatments and a new study of aspirin’s potential use in preventing the disease.
In a clinical trial presented at the recent European Society for Medical Oncology (ESMO) conference, the bispecific antibody zanidatamab from Jazz Pharmaceuticals posted a 59% survival rate at 30 months in patients with HER2-positive gastric cancer who received the drug with chemotherapy. Zanidatamab simultaneously targets two non-overlapping epitopes of HER2.
I-Mab’s investigational drug givastomig, a bispecific antibody targeting CLDN18.2 and the immune marker 4-1BB, showed promising efficacy as a solo treatment for gastric cancer patients in an early trial.
An analysis of data from nearly 13,000 gastric cancer patients in six countries, published in Cancer by the American Cancer Society, revealed that aspirin use had a protective effect that was strongest in people without a family history of the disease. Statin use did not protect against the disease. Both drugs have been associated with cancer protection in the past, though study results have been mixed. The authors suggested that further research be performed to confirm the utility of aspirin for cancer prevention in high-risk individuals.
| 
